Results 61 to 70 of about 1,341 (168)

Long-Term Follow-Up of a Case of Severe Hyperglycemia Requiring Hospitalization after Third Dose of Teprotumumab: A Case Report

Case Reports in Ophthalmology
Introduction: In 2020, teprotumumab became the first FDA-approved treatment for thyroid eye disease (TED). In clinical trials, hyperglycemia had been described as mild and controlled with medication.
Preeya Mehta, Trevor Angell, Vivian LeTran, Michael Lin, Annie Nguyen, Sandy Zhang-Nunes   +5 more
doaj   +1 more source

Outcomes of Strabismus Surgery Following Teprotumumab Therapy

PURPOSE: To investigate the results of patients undergoing surgical treatment for strabismic diplopia in thyroid eye disease (TED) following teprotumumab. DESIGN: Multicenter, retrospective, case series.
Peragallo, Jason H, Pruett, Jaron, Ditta, Lauren, Kuo, Annie F, Tavakoli, Mehdi, Indaram, Maanasa, Hilliard, Grant, Velez, Federico G, Kerr, Natalie C, Hoehn, Mary E, Donahue, Sean P   +10 more
core   +1 more source

Thyroid Eye Disease Relapse After Teprotumumab Therapy: A Case Report

, 2022
Teprotumumab is a monoclonal antibody that acts by blocking the IGF-1R and has been approved as a \u27breakthrough therapy\u27 for treatment of Thyroid Eye Disease (TED).
Ricaurte R. Crespo Trevino; Francisco Sanchez Moreno; Jade Schiffman; Daniel Uribe Padilla; Rosa Tang
core  

Towards targeted Cas9 (CRISPR‐Cas) delivery: Preparation of IgG antibody‐Cas9 conjugates using a split intein

Journal of Peptide Science, Volume 30, Issue 7, July 2024.
Precise cellular targeting will expand the potential of CRISPR‐Cas‐mediated gene editing. For linking the large Cas9 enzyme to IgG antibodies as prime targeting devices, protein trans‐splicing under non‐reducing conditions is shown to efficiently form the desired conjugate from the separately produced and purified entities, providing the first step of ...
Tim Pasch, Nicole Bäumer, Sebastian Bäumer, Frank Buchholz, Henning D. Mootz   +4 more
wiley   +1 more source

Comparative Efficacy of Medical Treatments for Thyroid Eye Disease: A Network Meta-Analysis

Journal of Ophthalmology, 2018
Purpose. Numerous medical strategies have been proposed for the treatment of thyroid eye disease (TED); however, the best methods for standard treatment are still a matter of controversy.
Nuo Xu, Yi Cui, Tianlu Xie, Mi Zheng
doaj   +1 more source

The circulating IL‐35+ regulatory B cells are associated with thyroid associated opthalmopathy

Immunity, Inflammation and Disease, Volume 12, Issue 5, May 2024.
The percentage of circulating IL‐35+Bregs was elevated in thyroid‐associated ophthalmopathy (TAO), and the increase was positively correlated with disease activity. IL‐35 significantly prompted the induction of IL‐35+Bregs in healthy controls, but the B cells in TAO showed potential impairment in the transition of B cells towards IL‐35+Breg phenotype ...
Qian Li, Cuixia Yang, Cheng Liu, Yuehui Zhang, Ningyu An, Xiumei Ma, Yang Zheng, Xiaomin Cui, Qian Li   +8 more
wiley   +1 more source

Rapid response of thyroid eye disease, peripheral edema, and acropathy to teprotumumab infusion

American Journal of Ophthalmology Case Reports
Purpose: We present a case of rapid improvement in symptoms of thyroid eye disease and amelioration of worsening peripheral edema and acropathy with infusion of teprotumumab, a monoclonal antibody targeting the insulin-like growth factor-1 receptor ...
David A. Kelly, Roger E. Turbin
doaj   +1 more source

Rescuing Drugs That are Discontinued in Adult Oncology Development for the Benefit of Children and Adolescents With Cancer – An ACCELERATE Multistakeholder Consensus

Clinical Pharmacology &Therapeutics, Volume 115, Issue 1, Page 36-41, January 2024.
Better therapies for childhood cancer remain an unmet need to improve the dismal prognosis of certain malignancies and to reduce the burden of toxicity. Rescuing discontinued or shelved drugs for children, adolescents, and young adults is a strategy to identify new uses for approved or investigational medicines outside the scope of their original ...
Teresa de Rojas, Davy Chiodin, Andrew D.J. Pearson, Delphine Heenen, Peter Adamson, Hubert Caron, Gilles Vassal   +6 more
wiley   +1 more source

Should I Have Teprotumumab or Surgery?

, 2023
Pathophysiology of thyroid eye disease/thyroid orbitopathy and teprotumumab: In orbitopathy, it is believed that there is a cross reaction of thyroid auto-antibodies with the thyrotropin receptor (TSHR) and the insulin growth factor receptor (IGFR) on ...
Alison V. Crum
core   +2 more sources

Adverse event reporting of the IGF-1R monoclonal antibody teprotumumab: a real-world study based on the US food and drug administration adverse event reporting system

Frontiers in Pharmacology
BackgroundTeprotumumab, an IGF-1R monoclonal antibody, has shown significant efficacy in treating thyroid eye disease (TED). However, since teprotumumab was launched in 2020 and first approved in the United States, there were limited reports of post ...
Jiawei Zhao, Yong Tao
doaj   +1 more source